‡a
Author's Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers
‡a
Author's Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients.
‡a
triplettherapywithpalbociclibtaselisibandfulvestrantinpik3camutantbreastcanceranddoubletpalbociclibandtaselisibinpathwaymutantsolidcancers
‡A
Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers
‡9
1
‡a
inactivatingnf1mutationsareenrichedinadvancedbreastcancerandcontributetoendocrinetherapyresistance
‡A
Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance
‡9
1
‡a
tumorhistologicalsubtypingdeterminedbyhormonereceptorsandher2statusdefinesdifferentpathologicalcompleteresponseandoutcometodosedenseneoadjuvantchemotherapyinbreastcancerpatients
‡A
Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients.
‡9
1
